Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
about
Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementRecent Treatment of Interstitial Lung Disease with Idiopathic Inflammatory MyopathiesIdiopathic inflammatory myopathiesRituximab in the treatment of inflammatory myopathies: a reviewIdiopathic inflammatory myopathies.Treatment of Clinically Amyopathic Dermatomyositis in adults: A Systematic Review.An overview of polymyositis and dermatomyositis.Pre-treatment ferritin level and alveolar-arterial oxygen gradient can predict mortality rate due to acute/subacute interstitial pneumonia in dermatomyositis treated by cyclosporine a/glucocorticosteroid combination therapy: a case control study [coFactors Associated with Interstitial Lung Disease in Patients with Polymyositis and Dermatomyositis: A Systematic Review and Meta-AnalysisClinical features of inflammatory myopathies and their association with malignancy: a systematic review in asian population.Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis.IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis/dermatomyositisClinical heterogeneity and outcomes of antisynthetase syndrome.Diagnosis, pathogenesis and treatment of myositis: recent advances.The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis.Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.Current pharmacological treatment of idiopathic inflammatory myopathies.Management of connective tissue diseases associated interstitial lung disease: a review of the published literature.Hypomyopathic dermatomyositis associated with interstitial lung disease and good response to mycophenolate mofetil: case-based review.Assessment of Mortality in Autoimmune Myositis With and Without Associated Interstitial Lung Disease.Long-term follow-up of 124 patients with polymyositis and dermatomyositis: Statistical analysis of prognostic factors.Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease.An Atypical Clinical Course of Anti-MDA5 Antibody-positive Interstitial Lung Disease in a Patient with Three Deteriorations in 9 years.Clinical effects of direct hemoperfusion using a polymyxin B-immobilized fiber column in clinically amyopathic dermatomyositis-associated rapidly progressive interstitial pneumoniasSerum interleukin 6 levels as a useful prognostic predictor of clinically amyopathic dermatomyositis with rapidly progressive interstitial lung disease.Systemic Autoimmune Diseases.The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease.Clinically amyopathic dermatomyositis with rapidly progressive interstitial pneumonia: The relation between the disease activity and the serum interleukin-6 level.Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.Two cases of autoimmune and secondary pulmonary alveolar proteinosis during immunosuppressive therapy in dermatomyositis with interstitial lung disease.Successful treatment with intravenous high-dose immunoglobulin for cardiomyopathy in dermatomyositis complicated with rapid progressive interstitial pneumonia.The correlation between miR-200c and the severity of interstitial lung disease associated with different connective tissue diseases.Anti-MDA5 Antibody-Positive Dermatomyositis Presenting with Cellulitis-Like Erythema on the Mandible as an Initial Symptom.Lung Involvements in Rheumatic Diseases: Update on the Epidemiology, Pathogenesis, Clinical Features, and Treatment.
P2860
Q26744705-37AA500C-88AA-4050-B668-D74F8D0B013DQ26798023-712F3D55-DB0D-44E7-9FF0-4413E1F8AE71Q27025125-3C703E24-6A6C-42CD-9E34-FBE9247373C2Q28077745-7BEDFF6D-D408-4136-9454-BD35FECB99BEQ33924451-6E20FC8A-4900-4344-9633-DA5EBD4E0076Q34526090-34FD510A-D4BD-44BC-A9A1-0AD0746B0AD9Q34667765-3DB4F84F-AF04-48A7-9B93-7FE109F88BDFQ35107728-8CA6AD4F-5886-41EB-BC70-AC02719AF1D0Q36015534-1219DD0F-67EF-4F5E-A21F-1275FA521A4BQ36692379-D31865BF-3C4C-419E-964F-85AE5AD65D2AQ37704772-EB639E9D-B175-44DF-B991-B905A5B11605Q37706152-C108C3F4-869B-45DE-9F9C-AA38A14467B1Q38116464-D55CF558-0E70-4071-A0C2-0F9F27BFC633Q38131849-4DD71940-5EE2-4101-A662-FE3D0EE2083FQ38258248-2B678E09-F961-41BA-B511-44EC18CEA823Q38607528-54024322-C07F-4618-B2B2-45FA4D36004AQ38680762-6A96DDAC-C192-4A38-B4B4-B728768E1920Q38793513-FBAF01D5-83CE-4CF8-9999-23ECA24FB730Q39147131-9D80DFFB-AAFC-4A89-B7AA-7EFF3D74E321Q39776324-E244AAD3-919E-4BA2-8AD8-A8603023D7E6Q40901486-B84B0E7D-E480-4424-B604-51AC80907707Q41532897-97FF4C3E-6B7F-4821-89F1-67C66E8654E8Q42147109-99A7EB8A-DAF5-4740-A15B-3437CC1F37AEQ42634230-60CFCFA3-0152-4E24-AE98-73176C34A944Q45773557-AA7E96D3-7841-46F3-8D26-B507B3E3D6D7Q46748760-12722E61-4E2F-4585-85C6-716B6E439E3FQ47659489-CF8249DD-33EB-453F-B0CB-0A78478EACCEQ47881134-5D7A7189-43C5-48B1-A877-AD11AFA86887Q51280183-8629E9B5-8F12-4225-9FAA-646343FFBD88Q51547408-21A0DAD4-DA7E-4391-BCBF-0625E240E116Q51586236-20F6FEF1-C5CC-46AF-97ED-516F6E95E0CAQ51700184-30F02326-FE95-47B3-807D-D873B43A9B29Q55256600-E880B3C6-4CCE-4A69-8F3B-67064ADEFB32Q55361229-7FA1A646-8453-4EBA-BD39-63E9A4534789
P2860
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@en
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@nl
type
label
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@en
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@nl
prefLabel
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@en
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@nl
P2093
P2860
P1476
Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
@en
P2093
Ran Nakashima
Tsuneyo Mimori
Yuji Hosono
P2860
P2888
P304
P356
10.1007/S11926-012-0246-6
P577
2012-06-01T00:00:00Z